HSA
ABCL icon

HBK Sorce Advisory’s AbCellera Biologics ABCL Stock Holding History

HBK Sorce Advisory’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Hold
26,183
– – ﹤0.01% 636
2026
Q1 		$137K Buy
26,183
+1,227
+5% +$4.42K ﹤0.01% 622
2025
Q4 		$78.9K Buy
+24,956
New +$111K ﹤0.01% 609

Other funds holding ABCL

TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.11B AUM 38.73% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
DRP
Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

HBK Sorce Advisory's ABCL Position: Q2 2026 in Review

HBK Sorce Advisory held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 26,183 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #636.

HBK Sorce Advisory first reported a position in ABCL in Q4 2025 and has held it in 3 quarters since. 62 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • HBK Sorce Advisory held 26,183 shares of AbCellera Biologics worth $155K as of Q2 2026.
  • HBK Sorce Advisory left its AbCellera Biologics share count unchanged in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of HBK Sorce Advisory's portfolio in Q2 2026, its #636 holding.
  • HBK Sorce Advisory first reported a position in AbCellera Biologics in Q4 2025 and has held it in 3 quarters since.
  • 62 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.